| pubmed-article:10327061 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C0332305 | lld:lifeskim |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C0442711 | lld:lifeskim |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:10327061 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:10327061 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:10327061 | pubmed:dateCreated | 1999-6-3 | lld:pubmed |
| pubmed-article:10327061 | pubmed:abstractText | A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA were extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5-8, and mutations of K-ras at exon 1. To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT-PCR. A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were significant factors for prognosis (P<0.0001, P=0.0083 and P=0.0004, respectively). Based on these results, we classified the patients into three groups according to their MRP-1/ CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild K-ras tumors were defined as group A, patients with either reduced MRP-1/CD9 or mutant K-ras tumors were defined as group B and patients with both reduced MRP-1/CD9 and mutant K-ras tumors were designated as group C. This new classification was significantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was significantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients was better than the group C patients (27.9% vs 20.0%, P=0.0378). This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9% vs 0.0%, P<0.0001). A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a significant prognostic effect as well as nodal status (P<0.0001). | lld:pubmed |
| pubmed-article:10327061 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10327061 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10327061 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10327061 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10327061 | pubmed:issn | 0950-9232 | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:HuangCC | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:KodamaKK | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:TakiTT | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:MiyakeMM | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:AdachiMM | lld:pubmed |
| pubmed-article:10327061 | pubmed:author | pubmed-author:HigashiyamaMM | lld:pubmed |
| pubmed-article:10327061 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10327061 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:10327061 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10327061 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10327061 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10327061 | pubmed:pagination | 2397-404 | lld:pubmed |
| pubmed-article:10327061 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:meshHeading | pubmed-meshheading:10327061... | lld:pubmed |
| pubmed-article:10327061 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10327061 | pubmed:articleTitle | A novel molecular staging protocol for non-small cell lung cancer. | lld:pubmed |
| pubmed-article:10327061 | pubmed:affiliation | Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. | lld:pubmed |
| pubmed-article:10327061 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10327061 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10327061 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10327061 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10327061 | lld:pubmed |
